Legislative Affairs

“One of the penalties of not participating in politics is that you will be governed by your inferiors.”

Plato

The mission of APCI’s Legislative Affairs division is to promote and protect the political and economic interests of all APCI members. In order to accomplish that mission, Legislative Affairs:

  • Provides lobbyist and/or legislative assistance in all APCI member states
  • Identifies pharmacy-friendly political candidates and generate funding to support them
  • Contributes to state associations and organizations with similar legislative focus
  • Identifies political leaders to meet and key meetings or conferences to attend
  • Establishes routine and structured legislative meetings in each state
  • Leverages APCI account representatives and staff personnel
  • Utilizes APCI's Board of Directors to attend selected legislative events
  • Encourages APCI member participation and support of NCPA
  • Maintains a Washington, D.C., presence, supporting NCPA and developing direct relationships

For more information about APCI's Legistative Affairs division, contact us or call (800) 532-2724.

6

Apr

2015

NCPA Advocacy Center Update 4.4.15

This week's advocacy update from NCPA includes news on Medicaid rates, abuse-deterrent opioids, and the 2015 NCPA Legislative Conference.

31

Mar

2015

NCPA Advocacy Center Update 3.30.15

This week's Advocacy Update from NCPA includes information on the status of legislation dealing with Medicare; CMS decisions regarding Aetna; and steps taken by HHS to combat opioid drug abuse.

23

Mar

2015

NCPA Advocacy Center Update 3.23.15

This week, the advocacy update includes details on the inclusion of provider status into a Senate budget bill, MTM legislation, and how TRICARE will cover compounded medications.

16

Mar

2015

NCPA Advocacy Center Update 3.16.15

In this week's Advocacy Update, NCPA provides details of a report to Congress dealing with preferred networks, TRICARE compound coverage, and more!

9

Mar

2015

NCPA Advocacy Center Update 3.7.15

In this week's advocacy front, NCPA submits call letter comments to CMS, the FDA approves its first biosimilar, and more!

First 72737475 Last